SCHEMBL3010044

SCHEMBL3010044

O=S(=O)(c1ccccc1Cl)N1CCN(c2nc(Cc3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45
RAB9A P51151 1/20 0.43
CHRM4 P08173 3/20 0.42
GBA1 P04062 2/20 0.40
CCR1 P32246 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
MAPK1 P28482 1/20 0.39
FAAH O00519 1/20 0.38
EPHX2 P34913 1/20 0.38
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008554 0.94 KMT2A (0.45) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3012178 0.93 LMNA (0.44) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3017801 0.92 KMT2A (0.45) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3015146 0.92 MAPT (0.43) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3019112 0.91 MAPT (0.44) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3015825 0.90 ALDH1A1 (0.44) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3017743 0.90 KMT2A (0.47) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3007155 0.90 TRPV4 (0.43) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3023917 0.90 ALDH1A1 (0.43) KMT2AMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL3002935 0.89 ALDH1A1 (0.43) KMT2AMAPTALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MAPT 18/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.